Altimmune (ALT) Net Equity Issued and Repurchased (2011 - 2026)
Altimmune (ALT) posted quarterly Net Equity Issued and Repurchased of $34.2 million for Q1 2026, down 1.58% year-over-year from $34.7 million in Q1 2025, and down 44.52% quarter-over-quarter from $61.6 million in Q4 2025.
Altimmune (ALT) Net Equity Issued and Repurchased (2011 - 2026) Analysis & Trends
Altimmune (ALT) has reported Net Equity Issued and Repurchased for 13 consecutive years, with $34.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Equity Issued and Repurchased fell 1.58% year-over-year to $34.2 million; the TTM figure through Mar 2026 stood at $173.2 million (up 60.36% YoY), while the FY2025 annual figure was $173.7 million, up 1638.37% from the prior year.
- Net Equity Issued and Repurchased retreated to $34.2 million in Q1 2026 per ALT's latest filing, from $61.6 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $72.7 million in Q4 2023 and bottomed at $510000.0 in Q3 2023.
- Historically, Net Equity Issued and Repurchased has averaged $33.7 million across 4 years, with a median of $34.5 million in 2025.
- Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased climbed 17.43% — and 2023, when it plunged 98.4%.
- Altimmune's Net Equity Issued and Repurchased stood at $31.8 million in 2022, then jumped by 128.53% to $72.7 million in 2023, then fell by 15.25% to $61.6 million in 2025, then tumbled by 44.52% to $34.2 million in 2026.
- Business Quant data shows ALT's Net Equity Issued and Repurchased at $34.2 million in Q1 2026, $61.6 million in Q4 2025, and $39.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Altimmune | 571.75 Mn | 571.75 Mn | - | 34.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.20 Mn |
| Jun 30, 2026 | 34.20 Mn |
| Mar 31, 2026 | 34.20 Mn |
| Mar 31, 2026 | 34.20 Mn |
| Dec 31, 2025 | 61.65 Mn |
| Dec 31, 2025 | 61.65 Mn |
| Sep 30, 2025 | 39.52 Mn |
| Sep 30, 2025 | 39.52 Mn |
| Jun 30, 2025 | 37.82 Mn |
| Jun 30, 2025 | 37.82 Mn |
| Mar 31, 2025 | 34.75 Mn |
| Mar 31, 2025 | 34.75 Mn |
| Dec 31, 2023 | 72.74 Mn |
| Dec 31, 2023 | 72.74 Mn |
| Sep 30, 2023 | 510,000.00 |
| Sep 30, 2023 | 510,000.00 |
| Sep 30, 2022 | 31.83 Mn |
| Sep 30, 2022 | 31.83 Mn |
| Jun 30, 2022 | 21.35 Mn |
| Jun 30, 2022 | 21.35 Mn |